Platelet Rich Plasma Improves Experimental Colitis in Rat Model

  Fatemeh Pour Mohammadi-Nejad - Department of Periodontics, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
  Aliakbar Yousefi-Ahmadipour - Department of Tissue Engineering and Applied Cell Sciences, Tehran University of Medical Sciences, Tehran, Iran

Background and Aim: Nowadays, platelet-rich plasma (PRP) has openeda new window for inflammatory disease such as osteoarthritis. PRP hasshown significant anti-inflammatory, therapeutic and trophic potential. In this study, we have designed an experiment to assess PRP therapypotential on experimental colitis model.Methods: Acute colitis in rat induced by intracolonic administrationof 50 mg/kg trinitrobenzene sulfonic acid (TNBS). Rats were dividedinto five groups: control group, TNBS group, sulfasalazine group, PRPgroup. Groups with PRP and sulfasalazine received a daily dose ofintraperitoneal injection of PRP and sulfasalazine, respectively. Bodyweight, disease activity index (DAI), colon length, colon weight to lengthratio were measuredResults: PRP significantly suppressed TNBS induced body weight loss,colon length shortening and decreased the colon weight to length ratio.Conclusion: The results of this study suggested that PRP as a newpromising therapeutic option for inflammatory diseases are able to showanti-inflammatory effects on colitis.

Cell therapy; Disease activity index; Platelet-rich plasma; Regeneration, Anti-inflammatory effects